Foundation Medicine

Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer

Retrieved on: 
Giovedì, Giugno 6, 2024
Sunnybrook Health Sciences Centre, Patient, Innovation, Immunotherapy, Liver disease, Foundation Medicine, Clinical trial, SSI, Site, Christianity in Singapore, Partnership, News, Executive, Cancer, The Ottawa Hospital, Pharmaceutical industry

BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc .

Key Points: 
  • BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc .
  • are pleased to announce a partnership aimed to impact the care of patients with late-stage colorectal cancer undergoing surgery.
  • Qu Biologics is currently enrolling patients with late-stage colorectal cancer undergoing surgical resection of liver metastases in a randomized, placebo-controlled Phase II multicenter trial ( PERIOP-06 ) to assess the effectiveness of QBECO SSI in reducing post-operative immune suppression and improving cancer outcomes.
  • Please subscribe here to receive future news and updates from Qu Biologics.

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Retrieved on: 
Mercoledì, Giugno 12, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Foundation Medicine, Therapy, Safety, Biomarker, ATR, PKMYT1, Food, FBXW7, CCNE1, PPP2R1A, Pharmaceutical industry

The companies are also exploring opportunities to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program.

Key Points: 
  • The companies are also exploring opportunities to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program.
  • Lunresertib is being evaluated alone and in combinations across several studies in the United States, Canada, European Union and United Kingdom.
  • Foundation Medicine is the global leader in companion diagnostic approvals with approximately 60% of all U.S. companion diagnostic approvals for next generation sequencing testing.
  • “We’re proud to partner with Repare Therapeutics as they work to advance this potential first-in-class therapy for patients with high unmet need.”
    Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Global Liquid Biopsy Market Forecast to 2031 - Initiatives, Funding, Major Deals, Company Profiles and Recent Developments - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Giugno 10, 2024
Genetics, Health, Oncology, Medical Supplies, NSCLC, Liquid biopsy, Patient, Prevalence, EVS, Research, Foundation Medicine, Lung cancer, Chinese, Growth, DNA, Neoplasm, Illumina, Inc., Biomarker, Physician, Laboratory, Kits, Hospital, Recurrence, NIPT, Circulating tumor DNA, Seminal vesicles, Breast cancer, Cancer, Medical imaging

The "Global Liquid Biopsy Market, Initiatives, Funding, Major Deals, Company Profiles and Recent Developments - Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Liquid Biopsy Market, Initiatives, Funding, Major Deals, Company Profiles and Recent Developments - Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
  • The global liquid biopsy market is predicted to reach US$ 13.72 Billion by 2031, from US$ 3.94 Billion in 2023.
  • The instruments segment is likely to witness the fastest growth in the global liquid biopsy market over the forecast period.
  • South America and Middle East & Africa are competing closely to grab the maximum share of the global liquid biopsy market.

United States Liquid Biopsy Market Forecast to 2031: Company Profiles, Recent Developments and Major Deals - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Giugno 10, 2024
Genetics, Health, Oncology, Medical Supplies, NSCLC, Reference, Incidence, Prognosis, Liquid biopsy, Blood, Patient, Prevalence, National Cancer Institute, EVS, Research, Foundation Medicine, Infection, Lung cancer, Chinese, Biomarker, Pain, Risk, DNA, Growth, Neoplasm, Illumina, Inc., Physician, Laboratory, Trisomy, Nucleic acid thermodynamics, Fetus, Kits, Death, Hospital, DSM-IV codes, Chromosome, Transplant, Rejection, Recurrence, NIPT, Circulating tumor DNA, Seminal vesicles, Breast cancer, Diagnosis, Cancer, Medical imaging

The "United States Liquid Biopsy Market (by Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application, End User, Clinical Application, Sample Type), Initiatives, Funding, Major Deals, Company Profiles, and Recent Developments - Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market (by Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application, End User, Clinical Application, Sample Type), Initiatives, Funding, Major Deals, Company Profiles, and Recent Developments - Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
  • The United States liquid biopsy market was valued at around US$ 1,200 Million in 2023, and the market is projected to reach US$ 3,807 Million by 2031.
  • The instruments segment is likely to witness the highest growth in the United States liquid biopsy market.
  • Based on application, the cancer segment accounted for largest share of the United States liquid biopsy market.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

Retrieved on: 
Mercoledì, Maggio 29, 2024
NCT, Partnership, Patient, DNA, CDX, Food, PMV, Prevalence, Clinical trial, FDA, TP53, Cancer, Fast Track, Foundation Medicine, Mutation, Physician, Pharmaceutical industry

“We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”

Key Points: 
  • “We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”
    Rezatapopt (PC14586) is an investigational, first-in-class, selective p53 reactivator designed to stabilize p53 Y220C proteins.
  • The TP53 Y220C mutation creates a small pocket in the p53 protein, making it thermally unstable and unable to effectively interact with DNA.
  • If the CDx and separately the therapy are approved, FoundationOne CDx would be the first companion diagnostic to identify patients with TP53 Y220C mutations who may be eligible for rezatapopt.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

Retrieved on: 
Mercoledì, Maggio 29, 2024
Science, Other Science, Research, Pharmaceutical, Medical Supplies, Oncology, Health, FDA, NCT, Partnership, Patient, DNA, CDX, Food, PMV, Prevalence, Clinical trial, TP53, Fast Track, Foundation Medicine, Mutation, Physician, Pharmaceutical industry

“We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”

Key Points: 
  • “We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”
    Rezatapopt (PC14586) is an investigational, first-in-class, selective p53 reactivator designed to stabilize p53 Y220C proteins.
  • The TP53 Y220C mutation creates a small pocket in the p53 protein, making it thermally unstable and unable to effectively interact with DNA.
  • If the CDx and separately the therapy are approved, FoundationOne CDx would be the first companion diagnostic to identify patients with TP53 Y220C mutations who may be eligible for rezatapopt.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting

Retrieved on: 
Venerdì, Maggio 24, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, ERBB2, Patient, Lung, Doctor of Philosophy, Cancer, DNA, Booth, AKT1, MBC, PBO, HER2, Circulating tumor DNA, Prevalence, PIK3CA, Endometrial cancer, TALA, Neoplasm, MD, Abstract, CGP, ASCO, Foundation Medicine, Talazoparib, RNA, Society, PTEN, Breast, Annual general meeting, Medical imaging

Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.

Key Points: 
  • Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.
  • “We are also excited to demonstrate our new RNA sequencing capabilities and spotlight the expanding utility of ctDNA to inform treatment decision making through a simple blood sample.”
    The following is a complete list of Foundation Medicine abstracts that will be presented.
  • To access the abstracts being presented at ASCO, please visit ASCO.org/abstracts .
  • Follow Foundation Medicine on LinkedIn , X and Instagram for more updates from #ASCO24 and visit us in person at Booth #22031.

Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S.

Retrieved on: 
Martedì, Maggio 21, 2024
Medical Supplies, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Genetics, Science, Patient, DNA, Bone marrow, Bladder cancer, Tracker, Lung cancer, Neoplasm, Liquid, NSCLC, Heme, Cholangiocarcinoma, MD, Blood, Pancreatic cancer, Cancer, Gene, Foundation Medicine, Sarcoma, RNA, Thyroid cancer, Physician, Monitor, Vaccine

Foundation Medicine, Inc. , today announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.

Key Points: 
  • Foundation Medicine, Inc. , today announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.
  • Foundation Medicine also offers circulating tumor DNA monitoring assays, including clinically available and tissue-informed FoundationOne®Tracker, and tissue-naïve FoundationOne®Monitor, which is currently available for research use.
  • “While DNA sequencing with optimized targeting using FoundationOne CDx can detect many fusions, RNA sequencing with FoundationOne RNA can provide another layer of sophisticated fusion detection in 318 genes,” says Mia Levy, MD, PhD, Chief Medical Officer, Foundation Medicine.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Diamond, FDA, Cancer, Foundation Medicine, Mutation, Investment, HGG, Food, Research, Lung cancer, GBM, Development, Administration, ASCO, TKI, Helmy Eltoukhy, BRAF, Patient, Society, G&A, AACR, Annual general meeting, Prevalence, NRAS, Pharmaceutical industry

Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.

Key Points: 
  • Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.
  • Net cash used in operations was $21.2 million for the first quarter of 2024 compared to $20.0 million for the first quarter of 2023.
  • Net Loss: Net loss for the first quarter of 2024 was $18.2 million, as compared to $20.9 million for the same period in 2023.
  • Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Maggio 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.